Wockhardt (WOCKPHARMA) — AI Technical & Fundamental Analysis
Detected Patterns
No patterns detected
Key Levels
| Level | Price (₹) |
|---|---|
| Entry | ₹2075.0 |
| Target | ₹2420.0 |
| Stop-Loss | ₹1910.0 |
| Support | ₹1940.0 |
| Resistance | ₹2152.9 |
AI Technical Analysis
{"technical": "WOCKPHARMA has formed a high-reliability Bull Flag pattern following an aggressive, near-vertical structural expansion. The 'pole' was established via a swift rally from ~\u20b91600 to a 3-month high of \u20b92152.9, satisfying the structural prerequisite of a \u226510% move within 10 sessions. The stock has since entered a tight, shallow consolidation (the 'flag') over the last 6 trading sessions, retracing roughly 15% of the preceding pole's gains. Volume during this consolidation phase has visibly contracted below its 20-day average, signaling a lack of institutional selling pressure. Price is currently resting inside the upper boundary of this flag channel at \u20b92072.9, perfectly positioned for a breakout. The structural moving average alignment is robustly bullish (SMA20 > SMA50 > SMA200), providing deep dynamic support, while a rising RSI of 76.6 combined with a massive ROC-10 of +29.6% and a 5-day volume ratio of 2.75x confirms high-velocity momentum.", "fundamental": "The company's quarterly financial performance reveals an explosive, accelerating growth trajectory that provides fundamentally backed momentum to the technical structure. Sales have steadily expanded sequentially from \u20b9355 crore in March 2025 to \u20b9516 crore in March 2026. More impressively, Net Profit has registered a multi-fold surge, skyrocketing from \u20b928 crore in the December 2025 quarter to \u20b9167 crore in the March 2026 quarter. This dramatic bottom-line expansion signals operational turnaround and strong operating leverage, fundamentally justifying the aggressive accumulation seen on the price chart.", "news": "Recent high-profile commentary titled 'How Wockhardt solved a problem Indian pharma couldn't' highlights a highly bullish narrative surrounding the company's research and development or clinical breakthrough capabilities. This narrative acts as a powerful institutional catalyst, amplifying market conviction and driving the aggressive volume expansion seen on major breakout tranches, which strongly reinforces the bullish continuation thesis.", "pattern_type": "continuation", "momentum_strength": "strengthening"}
Fundamentals
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).[1]
| Quarter | Revenue (Cr) | Net Profit (Cr) |
|---|---|---|
| Mar 2025 | 355 | 40 |
| Jun 2025 | 413 | 69 |
| Sep 2025 | 380 | 54 |
| Dec 2025 | 430 | 28 |
| Mar 2026 | 516 | 167 |
Get alerted when WOCKPHARMA hits key levels
Set price and news alerts for WOCKPHARMA — free on Android.
Download Investonks Free →WOCKPHARMA News Alerts Alert History AI Track Record All AI Picks